MRK ends nemtabrutinib development after phase III safety concerns, shifting focus to its expanding pipeline assets.

Moderna's Q3 2026 revenue of $1.3B and diluted EPS of $0.38 suggest a commercial rebound, yet trailing-twelve-month revenue remains down 39.2% and the trailing net margin stands at -145.2%, indicating the post-pandemic contraction has not been reversed.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue rebounded to $1.3B in Q3 2026 with a 75.8% gross margin, but the 9.9% operating margin follows multiple quarters of losses, including an operating margin of -126.4% in 2025Q4, suggesting the profit may be an isolated event.
Moderna is expected to launch over ten products by 2035, with a focus on respiratory vaccines and immuno-oncology, driving a Revenue CAGR of over +15% from 2026-2035.
Moderna specializes in mRNA therapeutics, leveraging its proprietary technology platform to develop innovative medicines, including vaccines and oncology treatments.
Moderna is making progress in its personalized cancer vaccine program, including late-stage data and collaborations with Merck, positioning it as a leader in immuno-oncology.
Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 6, 2026 | $0.38+134.5% vs -$1.10 | $1.3B+47.5% vs $890M |
Q3 2026 Jul 31, 2026 | -$1.97+3.0% vs -$2.03 | $145M+40.9% vs $103M |
Q2 2026 May 1, 2026 | -$3.40+23.6% vs -$4.45 | $389M+64.6% vs $236M |
Q1 2026 Feb 13, 2026 | -$2.11+16.9% vs -$2.54 | $678M+6.7% vs $635M |
MRK ends nemtabrutinib development after phase III safety concerns, shifting focus to its expanding pipeline assets.

Moderna, Inc. (MRNA) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Moderna NASDAQ: MRNA is preparing to file a U.S. application for its individualized cancer therapy intismeran by year-end, as executives outlined manufacturing plans and upcoming trial results following positive phase III melanoma data.
Banco Santander S.A. lowered its holdings in shares of Moderna, Inc. (NASDAQ: MRNA) by 34.7% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 56,612 shares of the company's stock after selling 30,065 shares during the period. Banco Santander S.A.'s holdings in Moderna were worth $10,902,000
Benchmark MRNA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Moderna, Inc. (MRNA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $206.80 | $82.06B | -31.88 | -39.23% | -110.46% | -37.62% | — | |
| $84.86 | $21.32B | -13.20 | 0.2% | -61.28% | -8.06% | — | |
| $7.96 | $1.31B | -17.11 | 64.69% | -18.64% | — | — | |
| $28.46 | $162.21B | 40.58 | -1.65% | 6.34% | 4.58% | 6.04% | |
| $278.70 | $670.89B | 42.40 | 6.05% | 16.2% | 19.55% | 1.83% | |
| $182.27 | $284.34B | 25.88 | 8.63% | 17.68% | 22.18% | 1.75% |
Moderna, Inc. (MRNA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Moderna, Inc. (MRNA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 6, 2026·SEC
Jul 31, 2026·SEC
Jul 8, 2026·SEC
Get notified when MRNA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Moderna, Inc. (MRNA) stock FAQ — growth, dividends, profitability & financials explained
Moderna, Inc. (MRNA) reported $2.52B in revenue over the trailing twelve months. Revenue was $1.94B in fiscal year 2025. That is 1693% more than the $108.4M of fiscal year 2016.
Moderna, Inc. (MRNA) grew revenue by 13.7% over the trailing twelve months, compared with the twelve months before.
No. Moderna, Inc. (MRNA) reported a net loss of $2.79B over the trailing twelve months.
Moderna, Inc. (MRNA) had a return on equity (ROE) of -37.6% over the trailing twelve months. A negative ROE means the company lost money over the period.
Moderna, Inc. (MRNA) had negative free cash flow of $1.95B over the trailing twelve months.